So far, the therapies scheduled to be part of the trial are risankizumab, an interleukin-23 antagonist, and lenzilumab, an anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody.
To estimate the association between attribute level and probability of choosing and receiving a vaccine, the study authors calculated the average marginal component effects sizes as well as marginal means.
The outbreak prompted the hospital’s infection control team to increase testing capacity, modify policies about social distancing and PPE, and review contact tracing protocol to keep patients and providers safe.
In patients with COVID-19 admitted to the ICU with a high acuity of illness and a prolonged period of mechanical ventilation, the time to start rehabilitation was often delayed because of the severity of an individual’s condition.
Researchers conducted a prospective study to analyze the relationship between continued angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB) use in the hospital and better clinical outcomes (ICU admission, morbidity, mortality).